Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Echografie van de milt die gebruik maakt van low-energy (diagnostisch niveau) insonificatie.

13 november 2026 bijgewerkt door: Jared Huston, Northwell Health

Effecten van echografie insonificatie van de milt op bloedplaatjesactiviteit en coagulatie biomarkers bij gezonde menselijke proefpersonen

This is a three-cohort, randomized, double-blinded , sham-controlled, single-center, early feasibility research trial to determine whether organ-specific biologic effects on platelet activity and coagulation are achievable through selective ultrasound of the spleen utilizing low-energy (diagnostic-level) insonification.

  • Group 1: Focused insonification at center of the spleen.
  • Group 2: Prolonged duration insonification at center of the spleen
  • Group 3: Prolonged duration insonification across the spleen.

Participants will receive 30 minutes of sham stimulation in the randomized group that is assigned to them, followed by active stimulation within the same group. Blood biomarkers (local and systemic) will be measured before and at several timepoints after stimulation to measure the molecular and cellular effects of the device

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

39

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • New York
      • Manhasset, New York, Verenigde Staten, 11030
        • Werving
        • Feinstein Institute for Medical Research
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 50 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria

  1. Provision of signed and dated informed consent form
  2. Willingness to comply with all study procedures and availability for the entire study duration
  3. Male or female, aged 18 to 50 years
  4. Individuals without physical disabilities or conditions/diseases that may make them incapable of undergoing the study procedure or otherwise places them at a greater risk of harm.
  5. Individuals without significant past medical or surgical histories that would render them at a greater risk of harm
  6. Individuals that are considered English Proficient due to the study requirements to follow verbal commands during the ultrasound session
  7. Individuals that are considered active as assessed by type of activity (i.e., walking, running, etc.) and number of hours a week performing the various activities
  8. Willing to adhere to the ultrasound study regimen
  9. Individuals able to attend all study visits at approximately the same time of day (i.e., 8-12 pm)
  10. Individuals able to comprehend the study goals and procedures, and can provide informed consent for participation

Exclusion Criteria:

  1. Individuals participating in another research study that may affect the conduct or results of this study

  2. Individuals considered substantially overweight or obese via body mass index (BMI > 30)

  3. Individuals having or exhibiting any of the following:

    • surgery in the past 90 days
    • previous surgery of the spleen or splenectomy, esophagus, lungs, stomach, duodenum, or liver
    • recent traumatic injury, including intracerebral hemorrhage and visceral injury
    • end stage renal disease and/or uremia
    • active malignancy
    • previous leukemia and/or lymphoma
    • human immunodeficiency virus infection or AIDS
    • rheumatoid arthritis or other immune-mediated diseases (e.g. inflammatory bowel disease)
    • arrhythmias, including but not limited to, atrial fibrillation, atrial flutter, clinically significant bradycardia, ventricular arrhythmias, and A-V block
    • implanted pacemaker or cardioverter/defibrillator (AICD)
    • history of stable or unstable angina, myocardial infarction, angioplasty, or coronary arterial by-pass grafting surgery
    • history of stroke or TIA
    • history of deep venous thrombosis (DVT) and/or pulmonary embolism (PE)
    • previous episodes of pancreatitis
    • spinal disorders
    • chronic pain syndromes
    • stage III-IV pressure ulcers
    • sickle cell anemia or other anemia syndromes
    • diagnosed with fever of unknown origin (FUO)
    • previously or currently implanted vagus nerve stimulator
    • previously or currently implanted spinal cord stimulator or other chronically implanted electronic medical device
    • history of seizures
    • history of cancer
  4. Individuals who have taken any of the following medications within two weeks of receiving ultrasound delivery:

    • anti-coagulants (warfarin, Xarelto)
    • anti-platelet agent (aspirin, clopidogrel)
    • anti-inflammatory (aspirin, NSAIDs)
    • anti-hypertensive (α-methyldopa)
    • epinephrine-related drugs, norepinephrine-related drugs, and drugs that stimulate release of epinephrine and/or norepinephrine (Micronefrin, Asthmanefrin)
    • immunosuppressive agents (steroids, newer immunomodulatory drugs)
    • alpha and/or beta-adrenoceptor blocking agents
    • anti-seizure medications
    • other medications, supplements, etc. that may interfere with the ultrasound delivery or study results
  5. Individuals with a substance abuse (alcoholism or other) problem

  6. Individuals that consumed alcohol within 7 days of the baseline visit

  7. Individuals currently using or have used cocaine, heroin, marijuana, or other illicit recreational drugs within the past 3 months

  8. Prisoners

  9. Participant has a history of thrombocytopenia (platelet count <100k)

  10. Participant has reported coagulopathy (elevated PT, PTT, elevated activated clotting time (ACT))

  11. Participant has internal bleeding, external bleeding, easy bruising

  12. Participant has a history of abnormal bleeding or blood disorder, including anemia or anemia-related disorders

  13. Participant has a history of thrombocytopenia (platelet count <100k)

  14. Participant has a history of coagulopathy, including hemophilia, stroke, pulmonary embolism, myocardial infarction, or deep vein thromboses

  15. Participant has a history of conditions that can cause coagulopathic conditions, including atrial fibrillation, heart valve surgery or replacement, hip or knee replacement, or clotting disorders

  16. Participants using coagulation- or platelet-modifying therapies such as clotting factor products, emicizumab, desmopressin acetate, epsilon amino caproic acid, heparin and its derivatives, argatroban, desirudin, bivalirudin, dabigatran, apixaban, edoxaban, betrixaban

  17. Participant has a history of chronic tobacco use or has ingested nicotine via smoking, vaping, smokeless tobacco, or nicotine patches in the past three months

  18. Participant has consumed caffeine within the past 12 hours

  19. Participant has received a blood transfusion within 30 days prior to study

  20. Participant has a history of neurologic diseases or traumatic brain injury

  21. Women of childbearing potential, not using adequate contraception as per investigator judgment or not willing to comply with contraception for the duration of the study

  22. Females who are pregnant, lactating or menstruating

  23. Participant has any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants are risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Fundamentele wetenschap
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Gerichte insonificatie bij Enter of milt

Ultrasound pulsed doppler system accompanied with the abdominal curvilinear probe will be used for the purpose of collecting the data for the endpoints.

Experimenteel: Langdurige insonificatie in het midden van de milt

Ultrasound pulsed doppler system accompanied with the abdominal curvilinear probe will be used for the purpose of collecting the data for the endpoints.

Experimenteel: Langdurige insonificatie geveegd over de milt

Ultrasound pulsed doppler system accompanied with the abdominal curvilinear probe will be used for the purpose of collecting the data for the endpoints.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
To determine whether diagnostic-level ultrasound to the spleen can modulate systemic blood biomarkers of hemostasis
Tijdsspanne: 4 hours

The primary objective is to determine whether diagnostic-level ultrasound to the spleen can modulate systemic blood biomarkers of hemostasis.

4 hours

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Medewerkers

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

8 januari 2026

Primaire voltooiing (Geschat)

7 juni 2027

Studie voltooiing (Geschat)

31 augustus 2027

Studieregistratiedata

Eerst ingediend

2 april 2025

Eerst ingediend dat voldeed aan de QC-criteria

16 april 2025

Eerst geplaatst (Werkelijk)

18 april 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

17 november 2026

Laatste update ingediend die voldeed aan QC-criteria

13 november 2026

Laatst geverifieerd

1 augustus 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • 24-0307

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Ja

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren